KalVista Pharmaceuticals
KALV
KALV was delisted on the 10th of June, 2026.
93 hedge funds and large institutions have $459M invested in KalVista Pharmaceuticals in 2023 Q4 according to their latest regulatory filings, with 14 funds opening new positions, 46 increasing their positions, 22 reducing their positions, and 22 closing their positions.
109% more repeat investments, than reductions
Existing positions increased: 46 | Existing positions reduced: 22
90% more call options, than puts
Call options by funds: $21.3M | Put options by funds: $11.3M
33% more funds holding in top 10
Funds holding in top 10: 3 → 4 (+1)
31% more capital invested
Capital invested by funds: $349M → $459M (+$109M)
2.9% more ownership
Funds ownership: 105.42% → 108.32% (+2.9%)
8% less funds holding
Funds holding: 101 → 93 (-8)
36% less first-time investments, than exits
New positions opened: 14 | Existing positions closed: 22
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VA
VR Adviser
New York
|
+$10.7M |
| 2 |
Morgan Stanley
New York
|
+$6.32M |
| 3 |
BlackRock
New York
|
+$5.43M |
| 4 |
FLSM
Frazier Life Sciences Management
Palo Alto,
California
|
+$3.49M |
| 5 |
WP
Woodline Partners
San Francisco,
California
|
+$3.16M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
LGM
Logos Global Management
San Francisco,
California
|
-$8.67M |
| 2 |
MB
MPM BioImpact
Boston,
Massachusetts
|
-$5.57M |
| 3 |
First Manhattan
New York
|
-$3.78M |
| 4 |
Adage Capital Partners
Boston,
Massachusetts
|
-$3.2M |
| 5 |
OM
Opaleye Management
Boston,
Massachusetts
|
-$3.18M |
KALV Hedge Fund Activity: Q4 2023 in Review
93 of the 6,860 institutional investors tracked by Wall St. Rank reported a position in KalVista Pharmaceuticals (KALV) for Q4 2023, worth a combined $459M — up 31% from $349M a quarter earlier.
Sellers outnumbered buyers: 22 funds closed out of KALV and 14 opened new positions — a net loss of 8 holders — while 22 trimmed existing stakes and 46 added.
The largest buyer was VR Adviser, adding an estimated $10.7M. The largest seller was Logos Global Management, exiting entirely with an estimated $8.67M sold.
- 93 institutional investors held KalVista Pharmaceuticals (KALV) as of Q4 2023, down from 101 in Q3 2023.
- Funds reported $459M of KalVista Pharmaceuticals stock for Q4 2023, up 31% quarter-over-quarter.
- 14 funds opened new KalVista Pharmaceuticals positions in Q4 2023 and 22 closed out, a net change of -8 holders.
- The largest KalVista Pharmaceuticals buyer in Q4 2023 was VR Adviser, an estimated $10.7M added.
- The largest KalVista Pharmaceuticals seller in Q4 2023 was Logos Global Management, an estimated $8.67M sold.
Based on aggregated 13F filings for Q4 2023.